{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:26:48Z","timestamp":1792758408220,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.japh.2022.12.015","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T20:33:22Z","timestamp":1671136402000},"page":"751-759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Demographic and socioeconomic correlates to buprenorphine access in pharmacies"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6418-744X","authenticated-orcid":false,"given":"Justine W.","family":"Welsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4216-931X","authenticated-orcid":false,"given":"Courtney R.","family":"Yarbrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siara I.","family":"Sitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4809-2621","authenticated-orcid":false,"given":"Maggie J.","family":"Mataczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Peralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie D.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahbia A.","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-8858","authenticated-orcid":false,"given":"Caroline","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-3288","authenticated-orcid":false,"given":"Henry N.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.japh.2022.12.015_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harv Rev Psychiatry"},{"issue":"2","key":"10.1016\/j.japh.2022.12.015_bib4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.japh.2022.12.015_bib6","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.japh.2022.12.015_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.japh.2022.12.015_bib8","article-title":"Buprenorphine for managing opioid withdrawal","volume":"2","author":"Gowing","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.japh.2022.12.015_bib9","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"15","key":"10.1016\/j.japh.2022.12.015_bib10","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for management of opioid use disorder","volume":"76","author":"Koehl","year":"2019","journal-title":"Am J Health Syst Pharm"},{"issue":"10118","key":"10.1016\/j.japh.2022.12.015_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.japh.2022.12.015_bib13","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis","volume":"24","author":"Ma","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.japh.2022.12.015_bib14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addbeh.2015.07.030","article-title":"Bridging waitlist delays with interim buprenorphine treatment: initial feasibility","volume":"51","author":"Sigmon","year":"2015","journal-title":"Addict Behav"},{"key":"10.1016\/j.japh.2022.12.015_bib15","doi-asserted-by":"crossref","first-page":"108140","DOI":"10.1016\/j.jsat.2020.108140","article-title":"Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program","volume":"119","author":"Jakubowski","year":"2020","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"8","key":"10.1016\/j.japh.2022.12.015_bib16","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1360-0443.2009.02570.x","article-title":"Mortality among opiate users: opioid maintenance therapy, age and causes of death","volume":"104","author":"Clausen","year":"2009","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.japh.2022.12.015_bib17","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/pds.4984","article-title":"Rise and regional disparities in buprenorphine utilization in the United States","volume":"29","author":"Pashmineh Azar","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.japh.2022.12.015_bib18","first-page":"112","article-title":"The geographic impact of buprenorphine expansion to nurse practitioner prescribers in Oregon","volume":"38","author":"Klein","year":"2022","journal-title":"J\u00a0Rural Health"},{"issue":"2","key":"10.1016\/j.japh.2022.12.015_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/10775587211004311","article-title":"The association between scope of practice regulations and nurse practitioner prescribing of buprenorphine after the 2016 opioid bill","volume":"79","author":"Nguyen","year":"2022","journal-title":"Med Care Res Rev"},{"issue":"5","key":"10.1016\/j.japh.2022.12.015_bib20","first-page":"976","article-title":"Traveling towards disease: transportation barriers to health care access","volume":"38","author":"Syed","year":"2013","journal-title":"J\u00a0Community Health"},{"issue":"1","key":"10.1016\/j.japh.2022.12.015_bib21","first-page":"108","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update","volume":"35","author":"Andrilla","year":"2019","journal-title":"J\u00a0Rural Health"},{"key":"10.1016\/j.japh.2022.12.015_bib22","doi-asserted-by":"crossref","first-page":"102701","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"8","key":"10.1016\/j.japh.2022.12.015_bib25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJMp2002908","article-title":"When prescribing isn\u2019t enough - pharmacy-level barriers to buprenorphine access","volume":"383","author":"Cooper","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.japh.2022.12.015_bib26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ajhp\/zxab003","article-title":"Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic","volume":"78","author":"Peckham","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.japh.2022.12.015_bib27","doi-asserted-by":"crossref","first-page":"103703","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"\u2018Red flags\u2019 and \u2018red tape\u2019: telehealth and pharmacy-level barriers to buprenorphine in the United States","volume":"105","author":"Textor","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"2013 11","key":"10.1016\/j.japh.2022.12.015_bib30","first-page":"1","article-title":"Causes and consequences of rural pharmacy closures: a multi-case study","author":"Todd","year":"2013","journal-title":"Rural Policy Brief"},{"issue":"2","key":"10.1016\/j.japh.2022.12.015_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on p-values: context, process, and purpose","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"key":"10.1016\/j.japh.2022.12.015_bib35","doi-asserted-by":"crossref","first-page":"108729","DOI":"10.1016\/j.drugalcdep.2021.108729","article-title":"Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden","volume":"224","author":"Kazerouni","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.japh.2022.12.015_bib36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/08897077.2019.1616349","article-title":"Pharmacists\u2019 attitudes toward dispensing naloxone and medications for opioid use disorder: a scoping review of the literature","volume":"40","author":"Muzyk","year":"2019","journal-title":"Subst Abuse"},{"key":"10.1016\/j.japh.2022.12.015_bib37","doi-asserted-by":"crossref","first-page":"103321","DOI":"10.1016\/j.drugpo.2021.103321","article-title":"Socio-ecological and pharmacy-level factors associated with buprenorphine stocking at pharmacies in New York City","volume":"97","author":"Marotta","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"3","key":"10.1016\/j.japh.2022.12.015_bib38","doi-asserted-by":"crossref","first-page":"100179","DOI":"10.1016\/j.ajogmf.2020.100179","article-title":"Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis","volume":"2","author":"Link","year":"2020","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"3","key":"10.1016\/j.japh.2022.12.015_bib39","first-page":"185","article-title":"Buprenorphine and naloxone versus buprenorphine for opioid use disorder in pregnancy: a cohort study","volume":"14","author":"Mullins","year":"2020","journal-title":"J\u00a0Addict Med"},{"issue":"2","key":"10.1016\/j.japh.2022.12.015_bib40","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.japh.2021.10.002","article-title":"Ensuring buprenorphine access in rural community pharmacies to prevent overdoses","volume":"62","author":"Ostrach","year":"2022","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"6","key":"10.1016\/j.japh.2022.12.015_bib41","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/add.15314","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA","volume":"116","author":"Hill","year":"2021","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.japh.2022.12.015_bib42","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.japh.2021.04.014","article-title":"Switching pharmacies leads to gaps in medication possession in individuals treated with buprenorphine","volume":"61","author":"Varisco","year":"2021","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"2S","key":"10.1016\/j.japh.2022.12.015_bib43","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.japh.2016.12.070","article-title":"Pharmacists\u2019 readiness to provide naloxone in community pharmacies in West Virginia","volume":"57","author":"Thornton","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2022.12.015_bib44","doi-asserted-by":"crossref","first-page":"109192","DOI":"10.1016\/j.drugalcdep.2021.109192","article-title":"Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex \u2013 United States, March 2019 \u2013 December 2020","volume":"232","author":"Cremer","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2022.12.015_bib45","doi-asserted-by":"crossref","first-page":"108272","DOI":"10.1016\/j.jsat.2020.108272","article-title":"Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic","volume":"124","author":"Wang","year":"2021","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.japh.2022.12.015_bib46","doi-asserted-by":"crossref","first-page":"108196","DOI":"10.1016\/j.jsat.2020.108196","article-title":"Medication treatment for opioid use disorder in the age of COVID-19: can new regulations modify the opioid cascade?","volume":"122","author":"Nunes","year":"2021","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.japh.2022.12.015_bib47","doi-asserted-by":"crossref","first-page":"108444","DOI":"10.1016\/j.jsat.2021.108444","article-title":"Low-barrier buprenorphine during the COVID-19 pandemic: a rapid transition to on-demand telemedicine with wide-ranging effects","volume":"131","author":"Buchheit","year":"2021","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.japh.2022.12.015_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211022994","article-title":"U.S. student pharmacist perceptions of the pharmacist\u2019s role in methadone for opioid use disorder: a qualitative study","volume":"9","author":"Hohmeier","year":"2021","journal-title":"SAGE Open Med"},{"issue":"1","key":"10.1016\/j.japh.2022.12.015_bib49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/CEH.0000000000000233","article-title":"Changes in pharmacists\u2019 perceptions after a training in opioid misuse and accidental overdose prevention","volume":"39","author":"Eukel","year":"2019","journal-title":"J\u00a0Contin Educ Health Prof"},{"issue":"8","key":"10.1016\/j.japh.2022.12.015_bib50","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.sapharm.2018.07.011","article-title":"Moving opioid misuse prevention upstream: a pilot study of community pharmacists screening for opioid misuse risk","volume":"15","author":"Strand","year":"2019","journal-title":"Res Social Adm Pharm"},{"issue":"6","key":"10.1016\/j.japh.2022.12.015_bib51","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.japh.2020.06.008","article-title":"Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: a descriptive analysis","volume":"60","author":"Salwan","year":"2020","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"3","key":"10.1016\/j.japh.2022.12.015_bib52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/10826084.2019.1670210","article-title":"Communication experiences of DATA-waivered physicians with community pharmacists: a qualitative study","volume":"55","author":"Ventricelli","year":"2020","journal-title":"Subst Use Misuse"},{"issue":"2","key":"10.1016\/j.japh.2022.12.015_bib53","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jac5.1556","article-title":"Pharmacists and opioid use disorder care during COVID-19: call for action","volume":"5","author":"Mohammad","year":"2022","journal-title":"J\u00a0Am Coll Clin Pharm"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122004113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122004113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:51:17Z","timestamp":1761544277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319122004113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1544319122004113"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2022.12.015","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Demographic and socioeconomic correlates to buprenorphine access in pharmacies","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2022.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}